The first 100 patients in the U.S. treated with OssDsign Catalyst
Uppsala, June 13, 2022. OssDsign AB (publ.) today announces that the first 100 patients in the U.S. have now been treated with the company’s innovative synthetic bone graft OssDsign Catalyst. The product was launched in the U.S. market in August, 2021, and has since then been rapidly adopted by surgeons for use in spinal fusion surgeries. The achievement marks an important milestone as OssDsign continues to grow its commercial presence.OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a